Monday, 2nd May 9th Australasian Vaccines & Immunotherapeutics Development Meeting 2022

• Design and evaluation of SARS-CoV-2 RBD mRNA vaccines  - Colin Pouton
• Covax19/Spikogen®, a novel adjuvanted recombinant spike protein Covid-19 vaccine   - Nikolai Petrovsky
• Developing a 'warm' vaccine to combat SARS-CoV-2 variants of concern and address inequity - S.S. Vasan

• Challenges for therapeutic antibody development and roll-out in response to pandemics - Alberto Stella
• Neutralising antibodies and COVID  - Stephen Kent
• A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19  - Nigel McMillan

• Metabolic disease reduces anti-viral immunity - Kirsty Short
• COVID-19 vaccines and variants: studies from Singapore - Barnaby Young
• Complete protection by a single dose skin patch delivered SARS-CoV-2 vaccine - Christpopher LD McMillan
• Measurement of dimeric IgA antibodies in SARS-CoV-2 patients using ELISA and unique profile of dimeric IgA in SARS-CoV2 infection - Helen WEI

3:00 PM   Roundtable Discussion: Taking COVID-19 vaccines to the clinic, what has it taught us?

Chair: Steven Rockman

• Engineering a smarter class of Chimeric Antigen Receptor T cells - Rebecca C Abbott
• Advancing vaccine research with biologically assembled biopolymers - Devi Jenika
• A controlled infection immunisation (CII) strategy for a malaria vaccine   - Reshma J. Nevagi
• Enhanced isolation rates of influenza viruses in a qualified cell line compared to embryonated hens eggs improves the probability of well-matched influenza vaccines - Heidi Peck
• Modulation of the renin-angiotensin system to reduce immunopathology in SARS-CoV-2 and influenza A infection - Melanie Wu
• Assessing vaccine and therapeutic efficacy against high consequence pathogens - Sarah J Edwards
• Fast Trak™ your molecule to market  - David Mabon
• Development of a scalable adeno-associated virus production process by transient transfection in suspension cells - Stephen O'Sullivan
• Development of a scalable adeno-associated virus purification process and an SPR titer assay - Tim O'Meara
• A Novel Role for Interleukin-22-signalling in Modulating Mucosal Epithelial Cell Antigen Presentation Machinery to Control Disease - M Arifur Rahman
• Ablation of CD8⁺ T-cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron    - Srividhya Swaminathan
• Selenium-GPX4 axis protects follicular helper T cells from ferroptosis and safeguards vaccine response - Di Yu
• Silencing pulmonary sensory neurons increases influenza disease severity - Nathalie A.J. Verzele
• Resistance of SARS-CoV-2 omicron to potent humoral responses and clinical immunotherapeutics relative to previous variants of concern - Gregory J Walker
• Towards development of novel peptide subunit vaccine for Tuberculosis - Viet Tram Duong